Board Member
Mereo BioPharma Group plc (MREO)Equibles does not estimate personal net worth.
Get an email with a short summary when Mereo BioPharma Group plc publishes a filing, an earnings call transcript or a press release.
Get MREO alertsDr. Denise Scots-Knight is recorded as CEO and Board Member at Mereo BioPharma Group plc (MREO). The newest filing on record that lists Dr. Denise Scots-Knight as CEO and Board Member at Mereo BioPharma Group plc (MREO) is dated April 9, 2026. The proxy statement of Mereo BioPharma Group plc reports total compensation of $2,219,323 for Dr. Denise Scots-Knight in fiscal 2023, including a base salary of $565,107. Disclosed compensation is on record for 2 fiscal years. Dr. Denise Scots-Knight has spoken on 1 investor event across 1 company, most recently for Mereo BioPharma Group plc on June 2, 2026. Mereo BioPharma Group plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mereo BioPharma Group plc includes Michael S. Wyzga (Chairman), Christine Fox (CFO), Charles Sermon (General Counsel) and 7 others.
“So, Moreo, we're a rare disease company. We have two late-stage programs, citruzumab for osteogenesis imperfecta, which is partnered with Ultrogenics, and we recently announced the phase three data, and we're currently having regulatory interactions, which I know we're going to come on to.”
Start not stated–present
Last confirmed April 9, 2026
Start not stated–present
Last confirmed April 9, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Mereo BioPharma Group plc (MREO) | Chief Executive Officer | $565,107 | $2,219,323 |
| 2022 | Mereo BioPharma Group plc (MREO) | Chief Executive Officer | $506,809 | $2,237,247 |
